May 24, 2021 | Press Releases
CULVER CITY, Calif., May 24, 2021 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder and Executive Chairman Dr. Patrick Soon-Shiong will deliver a company presentation at the 2021 Jefferies Virtual Healthcare...
May 20, 2021 | Press Releases
Chemotherapy free regimen (with NK and T cell activation via Anktiva) in patients across multiple tumor types who failed checkpoint inhibitor therapy 140 patients accrued to date in this basket trial of checkpoint failures in lung cancer, melanoma, urothelial, head...
May 17, 2021 | Press Releases
The first-in-class, memory cytokine-enriched Natural Killer (m-ceNKÔ) cells are the patient’s own NK cells that have been enriched with cytokines, including ImmunityBio’s IL-15 superagonist Anktiva (N-803) The resulting cryopreserved m-ceNK cells have an enhanced...
May 4, 2021 | Press Releases
Durable complete response achieved in 7 of 9 (78%) CD20 sensitive patients who failed Rituxan® therapy in Phase 1 liquid tumor trial Of those patients who responded to the combination therapy of Anktiva™ plus Rituxan, 7 out of 7 (100%) achieved a complete response...
Apr 29, 2021 | Press Releases
Phase 2 Study Sponsored by U.S. Military HIV Research Program, Thai Red Cross AIDS Research Centre CULVER CITY, Calif., April 29, 2021 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Military HIV Research...
Apr 22, 2021 | Press Releases
As testing accelerates, company boosts manufacturing speed, output, and quality control with over 2 trillion cryopreserved NK cells ready for off-the-shelf use CULVER CITY, Calif., April 22, 2021– ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy...
